Asthma: Symptoms, Treatment, Monitoring & Red Flags

Asthma is best understood as a heterogeneous airway disease in which type 2 and non–type 2 inflammatory pathways interact with airway hyperresponsiveness and episodic smooth-muscle-mediated bronchoconstriction. Inflammation and remodelling explain why symptoms persist between obvious attacks, and why anti-inflammatory controllers—not bronchodilators alone—anchor management when disease is more than occasional.

Clinically, nurses and frontline teams track control (symptom frequency, night symptoms, reliever use, activity limits) and risk (exacerbations, oral steroid bursts, ED or ICU history). Objective testing bridges the gap between what patients report and how narrow airways behave day to day; it also guards against over-diagnosing asthma when alternative explanations fit better.

Paediatric and adult phenotypes differ: young children may wheeze with viruses without lifelong asthma, while occupational triggers, aspirin-exacerbated disease, obesity-related dyspnoea, and smoking overlap challenge blanket regimens—the same triad of assessment, inhaled delivery quality, and escalation literacy still scales across ages when adapted to local paediatric pathways.

International charts organise controllers and relievers by symptom burden and exacerbation risk. Precision copy is jurisdiction-specific—open the guideline PDF your service adopts (Global Initiative for Asthma strategic report pages, collaborative UK guideline NG245, Australian Asthma Handbook) before cloning numbers onto order sets.

↔On a small screen, swipe or scroll sideways to see the full table.

Maintenance-and-reliever ICS-formoterol strategies combine reliever plus anti-inflammatory dosing in authorised formularies only—credentialing and device literacy prerequisites apply.

Classic exacerbations intertwine audible wheeze, cough, chest tightness, and shortness of breath that worsen overnight, with exertion, cold air, antigen exposure, or viral illness. Nurses should quantify nocturnal waking, reliever dosing frequency, speech coherence, posture, accessory muscle recruiting, and ability to tolerate lying flat—all tie directly to bedside severity ladders.

Atypical or easily missed patterns

• Cough-variant asthma may lack audible wheeze—spirometry or supervised bronchodilator trials help.
• Exercise-induced bronchoconstriction presents with post-exertional cough or tightness minutes after stopping activity; overlap with deconditioning requires objective testing.
• Sensations of tightness without wheeze on exam—rely on history plus lung function, not auscultation alone.
• Older adults or people with obesity may attribute difficulty breathing to age or weight; consider function tests when exertional breathlessness exceeds peers or climbs on treatment.

Asthma emerges from interplay of predisposing genetics plus environmental loads: airway sensitisation phenotypes, early respiratory infections, tobacco or cannabis aerosols, airborne pollution, workplace sensitizers, and psychosocial stress. Viruses remain dominant catalysts; suppurative airway infection is comparatively unusual unless pneumonia or unresolved sinus infection co-exists. Confirmed IgE-mediated food allergy can intersect with brittle asthma counselling—coordinate with multidisciplinary allergy pathways when ingestion carries systemic risk.

Modifiable vs contextual

• Modifiable: smoking and vaping, poor inhaler technique, untreated rhinitis, workplace exposures, suboptimal vaccination where recommended.
• Contextual: prematurity history, parental asthma, childhood eczema/food allergy phenotype—guides expectations and preventive counselling but does not substitute for treatment.

Clinical assessment

Structured history captures triggers (including exercise and workplace exposures), steroid or biologic exposures, ICU-level events, aspirin/NSAID hypersensitivity timelines, vaccination status, inhaler substitutions, and recent viral illnesses. Tie examination findings to contemporaneous airflow during symptomatic spells and quieter intervals, noting symmetry, prolonged expiration, paradoxical abdominal motion during fatigue, and escalating workload—all aligned with bedside respiratory nursing assessment frameworks used in your service.

Laboratory investigations

• Blood eosinophils and total IgE may support type-2–biased phenotypes when biologics are contemplated—not required for every patient.
• Allergen-specific IgE or skin testing helps when allergic triggers change management (immunotherapy, environmental control).
• FeNO is used in some services to refine ICS decisions—availability and cut-offs are protocol-specific.

Objective lung function

Pulmonary function testing with post-bronchodilator spirometry remains the backbone where feasible. Peak flow monitoring helps track variability and anchors home action plans when technique is taught consistently.

Imaging

Routine chest X-ray is not needed for typical asthma but helps when fever, focal signs, suspected complication, or alternative diagnosis (pneumothorax, infiltrate) is in play.

Criteria / scoring used in practice

Guidelines combine symptom control questionnaires (e.g., ACT) with exacerbation history and lung function. Paediatric pathways add trial-of-therapy frameworks when spirometry is difficult—document rationale and timeline for reassessment.

• Asthma–COPD overlap or isolated COPD—smoking biomass history, structural emphysema, incompletely reversible FEV₁/FVC after bronchodilator.
• Heart failure with congestion—orthopnoea, elevated jugular profiles, corroborative natriuretic peptides or imaging.
• Pulmonary embolism when dyspnoea is abrupt, pleuritic, or hypoxic out of proportion to wheeze—investigate aligned with thromboprophylaxis policies.
• Vocal cord dysfunction—paradoxical glottic movement; inspiratory stridor prominent; laryngoscopy when suspected.
• Bronchiectasis, restrictive physiology, ACE-inhibitor cough, and anxiety-mediated hyperventilation patterns that desaturate only late.

First-line management

• Low-dose inhaled corticosteroid maintenance—for example fluticasone or budesonide preparations—adjusted to phenotype, age, inhaler affordability, and comorbidity.
• ICS/LABA fixed-dose devices when symptom control slips on monotherapy ICS—match actuator type with inspiratory flow limits.
• Reliever choice follows formulary directives: intermittent short-acting beta agonist via spacer or supervised nebuliser therapy during crises; ICS-formoterol MART substitutes those roles only after credentialing confirmation.

Exacerbation therapy (ward / emergency themes)

• Repeat scheduled inhalations guided by asthma attack protocol, titrate supplemental oxygen toward local SpO₂ corridors while watching for hypercapnic fatigue, and escalate to ICU bundle when scoring demonstrates failure between doses.
• Early oral prednisolone equivalent or parenteral steroid when exacerbation crosses moderate thresholds—coordinate glucose monitoring and GI prophylaxis per local norms.

Second-line / add-ons

• Montelukast for allergic or exercise-predominant patterns—monitor neuropsychiatric adverse-effect vigilance per pharmacovigilance programmes.
• LAMA add-on (e.g., tiotropium via respiratory physicians) in severe or overlap states when formulary supports it.
• Theophylline remains an infrequent add-on confined to centres with assay turnaround and cardiorespiratory monitoring capacity.
• Biologics (anti-IgE, anti–IL-5/5R, anti–IL-4Rα) for severe eosinophilic or allergic phenotypes—nurse-led injection programmes and reaction monitoring.

Special populations

• Pregnancy: Poorly controlled asthma harms mother and fetus more than appropriately dosed ICS—coordinate obstetric and respiratory reviews.
• Older adults: Watch osteopenia, cataracts, glaucoma risk with high-dose ICS; consider drug–drug interactions.
• Children: Age-appropriate spacers, parental education, school plans; growth monitoring with ICS—balanced messaging.

Workflow checkpoints

1. Suspected new disease: Objective testing → classify intermittent versus persistent burden → prescribe step-matched controllers → rehearse inhaler technique and reassess clinically in roughly 4–12 weeks depending on urgency.
2. Established asthma reviews: Screen daytime and nocturnal symptoms, reliever frequency, exacerbation tally, steroid exposure, vaccinations, adherence barriers, occupational triggers, mental health overlays—then reconcile devices with pharmacy records.
3. Escalate specialty referral early for occupational suspicion, peri-intubation histories, brittle courses despite step 4–5 therapy, diagnostic uncertainty, or biologic eligibility work-up queues.
4. Acute presentations: Apply structured scoring (PEF, vitals, speech, posture) alongside repeated bronchodilator administration, steroid decisions, monitored oxygen adjustment, arterial/venous gas triggers, ICU activation when fatigue dominates.

• Review interval: After any therapy step-up, recheck control in about 4–12 weeks; sooner if symptoms accelerate or reliever use climbs.
• Technique and adherence: Observed dose administration at every opportunity; explore cost, dexterity, and health-literacy barriers before labelling “refractory.”
• Drug interactions: Strong CYP inhibitors may raise concentrations of some methylxanthines; macrolides and theophylline combinations need pharmacy oversight.
• Treatment failure: Persistent ACT <20, ≥2 steroid bursts/year, or emergency care despite high ICS/LABA should trigger severe-asthma work-up—not endless dose stacking.
• Referral thresholds: Suspected occupational asthma, life-threatening attack, diagnostic uncertainty, or biologic eligibility—refer to respiratory/allergy clinics.
• MDT roles: Physiotherapists for breathing pattern disorders, pharmacists for device audits, specialists for biologic infusions—document who owns each follow-up task.

• Respiratory failure, pneumothorax, cardiac dysrhythmia from hypoxia or agonist toxicity.
• ICS-related oral candidiasis, dysphonia; rare adrenal suppression at high cumulative dose.
• Fixed airflow limitation from long-standing undertreated inflammation—a rationale for early control.
• Psychological comorbidity (panic, depression) amplifying symptom perception and healthcare use.

Clinician-facing prevention centers on sustained anti-inflammatory control, smoking cessation, up-to-date vaccinations recommended locally, occupational risk mitigation, and written action plans. Environmental mould or allergen remediation matters when sensitization is confirmed—not for every patient indiscriminately.

Many children experience remission or reduced severity; adults may remain stable for decades with good control. Prognosis darkens with smoking, recurrent intensive care admissions, brittle airway behaviour, or delayed access to specialist therapies—set realistic expectations while emphasizing that modern step care and biologics can transform quality of life when matched to phenotype.

• Pair bronchodilator teaching with spacer checks—patients often press the MDI once while inhaling fast; spend 90 seconds modelling slow inspiratory flow.
• Document the “unable to finish sentences” observation verbatim—it communicates severity faster than abstract scores during handoff.
• After systemic steroids, flag glucose checks for diabetes co-morbidity, sleep disturbance, and mood changes before discharge.
• Translate action-plan zones into nursing orders where protocol allows so night staff execute the same thresholds as day teams.

• Airway workload: RR, accessory muscles, ability to lie flat, speech, mental status.
• Peak flow or spirometry loops when cooperative—compare to personal best.
• Oxygen and gases: SpO₂ trend; screen for hypercapnia when fatiguing or receiving high-flow support.
• Therapy delivery: Spacer availability, neb mask seal, MDI actuation count aligned with order.
• Adjuncts: Encourage early mobilisation when stable post-exacerbation; incentive spirometry only where indicated to avoid breath-stacking distress.

• Struggling to speak, drowsy, or silent chest with weak air entry.
• Peak flow <50% best after initial bronchodilator or rapidly deteriorating.
• Central cyanosis, SpO₂ not responding to controlled oxygen, or syncope.
• First severe attack in pregnancy, or attack triggered by likely anaphylaxis.

Activate emergency medical systems for life-threatening patterns; where two-system allergic criteria coexist, follow anaphylaxis cart routes in parallel with bronchodilator escalation. Handoffs should include last treatment time, steroid route, and airway trajectory.

Objective cues

• Rising PaCO₂, falling pH, or exhaustion despite maximal initial therapy.
• New arrhythmia, ischaemic ECG changes from hypoxia.
• Increasing oxygen requirement to maintain lower-local target ranges.

Escalation ladder

• Ward nurse → primary responder / MET per early warning score breaches.
• Respiratory physician or ICU for possible NIV/intubation when indicated locally—asthma intubation is high-risk; involve experienced anaesthesia early.

Pre-exacerbation / clinic

• Run trigger inventories (work, pets, mould, viral season planning).
• Confirm steroid emergency card and school/work paperwork completeness.

During therapy

• Timed reassessments after bronchodilator stacks; chart response clearly for medicolegal traceability.
• Oral hydration, unless fluid restricted; align positioning with dyspnoea comfort.

Education and evaluation

• Teach-back on spacer cleaning, when to escalate, and steroid side effects.
• Success = stable peak flows, reduced unscheduled care, and patient able to verbalise red flags—measure at next contact.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and a compact cloze on the topic of chronic asthma assessment, the GINA / NAEPP-aligned stepwise pathway, ICS-formoterol MART stewardship and life-threatening exacerbation red flags.